Globus Medical Inc (NYSE:GMED) 2018 Q2 Sentiment Report

Globus Medical, Inc. (NYSE:GMED) Logo

Sentiment for Globus Medical Inc (NYSE:GMED)

Globus Medical Inc (NYSE:GMED) institutional sentiment increased to 1.18 in 2018 Q2. Its up 0.13, from 1.05 in 2018Q1. The ratio has improved, as 127 active investment managers increased and started new stock positions, while 108 cut down and sold stakes in Globus Medical Inc. The active investment managers in our partner’s database now have: 59.65 million shares, up from 58.46 million shares in 2018Q1. Also, the number of active investment managers holding Globus Medical Inc in their top 10 stock positions increased from 4 to 5 for an increase of 1. Sold All: 29 Reduced: 79 Increased: 80 New Position: 47.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company has market cap of $4.51 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches. It has a 31.95 P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.

The stock decreased 0.56% or $0.26 during the last trading session, reaching $45.79. About 48,769 shares traded. Globus Medical, Inc. (NYSE:GMED) has risen 72.10% since December 6, 2017 and is uptrending. It has outperformed by 56.48% the S&P500.

Analysts await Globus Medical, Inc. (NYSE:GMED) to report earnings on February, 20. They expect $0.40 earnings per share, up 5.26 % or $0.02 from last year’s $0.38 per share. GMED’s profit will be $39.38M for 28.62 P/E if the $0.40 EPS becomes a reality. After $0.39 actual earnings per share reported by Globus Medical, Inc. for the previous quarter, Wall Street now forecasts 2.56 % EPS growth.

Paradigm Capital Management Inc Ny holds 2.99% of its portfolio in Globus Medical, Inc. for 735,500 shares. Godshalk Welsh Capital Management Inc. owns 55,088 shares or 2.91% of their US portfolio. Moreover, Pura Vida Investments Llc has 2.89% invested in the company for 67,500 shares. The Illinois-based Oak Ridge Investments Llc has invested 2.36% in the stock. Van Berkom & Associates Inc., a Quebec – Canada-based fund reported 1.26 million shares.

Globus Medical, Inc. (NYSE:GMED) Ratings Coverage

Ratings analysis reveals 33% of Globus Medical’s analysts are positive. Out of 3 Wall Street analysts rating Globus Medical, 1 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $55 while the high is $64. The stock’s average target of $58 is 26.67% above today’s ($45.79) share price. GMED was included in 4 notes of analysts from June 27, 2018. The stock of Globus Medical, Inc. (NYSE:GMED) earned “Sell” rating by Bank of America on Wednesday, June 27. Morgan Stanley maintained the shares of GMED in report on Tuesday, September 25 with “Overweight” rating. On Thursday, August 2 the stock rating was maintained by Morgan Stanley with “Overweight”.

More notable recent Globus Medical, Inc. (NYSE:GMED) news were published by: which released: “Globus Medical Reports Second Quarter 2018 Results NYSE:GMED – GlobeNewswire” on August 01, 2018, also with their article: “Globus Medical Announces ExcelsiusGPS® Milestone: 3000 screws implanted – GlobeNewswire” published on June 26, 2018, published: “Globus Medical Enters Trauma Market NYSE:GMED – GlobeNewswire” on March 06, 2018. More interesting news about Globus Medical, Inc. (NYSE:GMED) were released by: and their article: “Globus Medical (GMED) Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” published on August 01, 2018 as well as‘s news article titled: “Globus Medical acquires Nemaris – Seeking Alpha” with publication date: September 13, 2018.

Globus Medical, Inc. (NYSE:GMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.